Understanding nephrogenic systemic fibrosis.

Area of Science:

• Nephrology
• Pathology
• Radiology

Background:

• Nephrogenic systemic fibrosis (NSF) is a rare, debilitating condition affecting patients with impaired renal function.
• NSF is linked to exposure to gadolinium-based contrast agents (Gd-CAs), particularly those with low stability.
• The pathogenesis involves cytokines activating macrophages and fibroblasts, leading to fibrotic lesions.

Purpose of the Study:

• To elucidate the underlying pathophysiological mechanisms of NSF.
• To correlate in vivo and in vitro experimental findings with clinical observations of NSF.
• To identify potential therapeutic targets in the early stages of fibrosis.

Main Methods:

• Review and collation of inferences from in vivo and in vitro experimental studies.
• Analysis of clinical observations related to NSF development.
• Incorporation of schematic representations of molecular pathways involved in NSF pathogenesis.

Main Results:

• Experimental studies indicate that cytokines, released from stimulated effector cells like macrophages and monocytes, activate circulating fibroblasts.
• These activated fibroblasts play a significant role in the development of NSF lesions.
• Permissive factors create an environment conducive to fibrosis development.

Conclusions:

• Understanding the molecular pathways, including receptor-mediated activation of macrophages and fibroblasts by gadolinium, is crucial for comprehending NSF pathogenesis.
• Further research into these mechanisms may reveal targets for early intervention in NSF.
• Current treatment modalities show variable success, highlighting the need for improved therapeutic strategies.